Independent U.S. Market Research

Biotech Catalysts, Stock Hubs & U.S. Small/Mid-Cap Research

Merlintrader publishes independent educational research on U.S.-listed biotech and small- and mid-cap stocks, with daily market briefings, FDA and PDUFA tracking, catalyst calendars and dedicated company hubs across biotech, space, defense, AI, cannabis, energy and critical minerals.

Merlintrader’s Daily Briefing

Saturday, August 22, 2026. Friday closed green and the week closed red: the Dow added more than five hundred points on the day and still lost ground over five sessions, the thirty-year yield rose again while equities rallied, and the strongest American business survey in more than four years arrived in the same week that the long end broke. Overnight, Ottawa suspended the trade negotiations and a fifty per cent American tariff took effect at midnight. American levels below are Friday closing prints.

Friday finished higher, the week finished lower
  • The closes — The S&P 500 rose 33.21 points, or 0.4 per cent, to 7,674.37. The Dow Jones Industrial Average rose 517.80 points, or 1.0 per cent, to 53,277.01. The Nasdaq Composite rose 113.29 points, or 0.4 per cent, to 26,180.45.Indices
  • The week — All three finished lower over five sessions: the S&P 500 down 111.39 points or 1.4 per cent, the Dow down 455.40 points or 0.8 per cent and the Nasdaq Composite down 548.71 points or 2.1 per cent. It is the second consecutive weekly decline for the Dow.Week
  • The funds — $SPY closed 0.41 per cent higher at 765.72, $QQQ 0.35 per cent higher at 713.44, $DIA 0.89 per cent higher at 532.22 and $IWM 0.77 per cent higher at 299.96. The Nasdaq 100 ended a five-session losing run.Funds
The long end rose alongside the stock market
  • The official curve — The Treasury’s own daily yield curve for August 21 shows the two-year at 4.24 per cent against 4.19 the day before, the ten-year at 4.74 against 4.69, the twenty-year at 5.25 against 5.20 and the thirty-year at 5.27 against 5.23. Every maturity moved up, and the front end moved with the back this time.Rates
  • What that undoes — The thirty-year is back within one basis point of the 5.28 per cent it printed on August 18, the highest in nearly two decades. The buyback the department doubled on Wednesday has now been fully retraced on the tape it was meant to support.Duration
  • The department’s position — The Treasury Secretary said on Friday he remains confident that yields will continue to decline. $TLT closed 0.35 per cent lower at 82.05, a sixth consecutive session of pressure on long-dated paper.Treasury
The fastest American business growth since April 2022
  • Flash composite — The S&P Global flash United States composite output index for August rose to 56.0 from 54.5 in July, the highest reading in fifty-two months. The services business activity index jumped to 56.8 from 54.6, a twenty-month high, while the headline manufacturing index slipped to 53.2 from 53.8, the weakest since March.Macro
  • Why it cuts both ways — The survey points to third-quarter growth approaching three per cent annualised against the 1.5 per cent pace of the second quarter. Growth of that order is the argument against rate cuts, which is one explanation for a session in which equities and yields rose together.Reading
Bitcoin closed its best week in two years
  • The level — Bitcoin reached about $77,000 on Friday, completing what reporting describes as its strongest week in two years, extending a move that began with Wednesday’s buyback announcement and a short squeeze.Crypto
  • The flows — United States spot bitcoin funds took in $608.3 million on Thursday, lifting the week above $1.6 billion and August to roughly $2.07 billion, already the highest monthly total of 2026 with several sessions still to run.ETF flows
  • The equity leg — $HOOD closed 13.70 per cent higher at $108.13, $COIN 8.20 per cent higher at $186.49 and $MSTR 6.10 per cent higher at $119.25. The financial sector fund $XLF added 0.93 per cent and was among the day’s better performers.Movers
  • The rule and the law — The Securities and Exchange Commission set out a new crypto regulatory framework on Friday. The Clarity Act, the market structure bill it would sit alongside, remains stalled in the Senate, which does not return until the middle of September. The equities are trading the rulemaking, not the statute.Policy
Ottawa suspended the talks and the tariff took effect
  • What was announced — The Canadian Prime Minister said on Friday evening that he had suspended trade negotiations with the United States and recalled his negotiators to Ottawa, citing last-minute changes in the American proposed terms that he called unfair and uneconomic.Trade
  • The size — The statement says the United States intended to impose a fifty per cent tariff on roughly twenty-eight billion dollars of Canadian goods at midnight, and that Canada will match those tariffs dollar for dollar. Further support measures for Canadian workers and businesses were promised in the coming days.Tariffs
  • When it lands on the tape — The announcement came after the American close, so no equity market has traded it. It arrives in the same week that a hard commodity bid and a rising long end were already in place.Timing
Gold, uranium and crude all closed the week higher
  • Metals — Gold held above $4,500 an ounce on Friday and finished a third consecutive weekly gain of close to five per cent. $GLD closed 1.95 per cent higher at 423.36, $SLV 1.72 per cent higher at 62.72 and the miners in $GDX 2.98 per cent higher at 102.83.Metals
  • Uranium — A second strong session in a row: $URA closed 5.09 per cent higher at 46.07, $CCJ 7.24 per cent higher at $102.51, $LEU 5.75 per cent higher at $186.26, $SMR 3.64 per cent higher at $9.40 and $OKLO 1.03 per cent higher at $42.09. No company release dated Friday explains the move on any of them.Uranium
  • Crude — West Texas Intermediate traded just below $87 a barrel and Brent above $93, both completing a second consecutive weekly gain of around five per cent on expectations of further American pressure on Iran. $XOP closed 1.11 per cent higher while the broader $XLE finished 0.17 per cent lower.Oil
The retail week ended with a third answer
  • $BJ — Comparable club sales rose 11.9 per cent, and 3.1 per cent excluding petrol. Membership fee income rose 9.9 per cent to $135.6 million on a record 8.5 million members, digitally enabled comparable sales grew thirty per cent, and diluted earnings were $1.36 a share. Full-year guidance is comparable sales excluding petrol up 2 to 3 per cent and adjusted earnings of $4.60 to $4.80. The stock closed 5.61 per cent higher at $96.42.Earnings
  • The three together — $ROST closed 4.39 per cent higher at $239.04 confirming Thursday evening’s beat, $WMT slipped a further 0.13 per cent to $103.70 after its nine per cent fall, and the warehouse club came in between them. Membership and off-price grew; the everyday-low-price bellwether did not.Consumer
Biotechnology and a decision dated today
  • $CAPR — The stock closed 7.97 per cent lower at $6.29 on 8.4 million shares. August 22, today, is the target action date the agency set for deramiocel in Duchenne cardiomyopathy after lifting last year’s complete response letter. On July 29 the advisory committee voted three in favour and nine against on effectiveness; that vote is not binding. No filing has been made with the Commission since August 13.Regulatory
  • $ZYME — Up 7.90 per cent at $28.67 into its own August 25 target date for zanidatamab, without a company release on Friday to explain the move.Catalyst
  • The sector — $XBI closed 1.44 per cent higher at 165.73, $IBB 1.29 per cent higher at 213.56 and $ARKG 3.80 per cent higher at 49.45. $MRNA added 8.86 per cent to $145.13, a second session of recovering the collapse that followed its own record gain.Biotech
  • Our names — $ETON closed 5.94 per cent higher at $63.47, $TVTX 1.94 per cent higher at $65.71, $VERA 3.25 per cent higher at $32.28 and $SLS 15.37 per cent higher at $15.46 on a third consecutive weekly gain. $IOVA gave back 7.79 per cent to $8.29 after four sessions of fresh highs.Watchlist
Tesla, Boeing and the tape’s two outliers
  • $TSLA — Closed 5.14 per cent higher at $362.86, the largest move among the megacaps, on clearance for a Las Vegas robotaxi deployment and coverage of a Semi launch aimed at Europe. In the same session the company was reported as leading China’s largest ever electric vehicle recall, alongside eight others, over concealed emergency door handles.Autos
  • $BA — Boeing’s engineers and technical workers rejected a four-year contract offer, engineers by 64.3 per cent and technicians by 71.9 per cent, and authorised a strike by 87.9 and 89.7 per cent respectively. The union has seventeen thousand members and the current contracts expire on October 6.Labour
Bottom line
  • What the week settled — A Treasury department that doubled its buybacks could not hold the long end for more than one session, and by Friday every maturity on the official curve was higher than it had been on Thursday. What worked over five sessions was gold, uranium, crude and the crypto brokers. What did not work was semiconductors, the retail bellwether and anything whose value depends on cheap long-dated money.Bottom line
  • What lands next — Nvidia reports on August 26, the Jackson Hole symposium runs from August 27 to 29 and is the first for the current Chair, and the personal consumption expenditures price index follows. The Canadian tariffs are already in force, and Capricor’s date is today.Calendar
What could not be verified
  • Method and limits — American equity and fund levels are Finviz Elite closing prints for August 21. Treasury yields are the department’s own published daily curve for August 21. The Canadian statement is quoted from the Prime Minister’s own release. The BJ’s figures come from the company release. The August flash purchasing managers’ figures are taken from coverage of the S&P Global release; the August release itself could not be opened directly on the S&P Global press page, where the document served was the June edition. Index point and percentage moves for the Dow, S&P 500 and Nasdaq Composite are as reported rather than taken from an exchange feed. Gold, silver and crude levels are quoted prices, not settlements. Bitcoin levels and fund flows come from market reporting, not from a fund issuer document. Consensus figures for the Nvidia quarter and market-implied probabilities for the September meeting are as reported and are not our own estimates.Method
Read the full Daily BriefingRead the Weekly Market Pulse

Biotech Catalyst Calendar 2026

Last updated: 22 July 2026

Merlintrader tracks upcoming biotech catalysts for U.S.-listed companies, including PDUFA dates, FDA decisions, clinical-trial readouts, advisory committee meetings and other regulatory milestones. Alongside each date you will find the source, company context and the key risks that can move the stock, plus links to deeper Merlintrader research when it is available. The focus is educational and risk-aware, with particular attention to small and mid-cap biotech names, where catalyst timing, cash runway and dilution risk can drive sharp moves in volatility. Dates can change and FDA decisions can arrive early or late, so always confirm an event against company filings and regulatory sources before acting on it.

Listed / exchange-traded biotech focus

Weekly Biotech Catalyst Tracker

Window covered: August 22 → September 30, 2026. Compact homepage board for unresolved FDA decisions, regulatory submissions and major clinical readouts. A prior-date item remains visible only when the regulatory process is still materially open; catalysts resolved in the past few days are retained briefly for continuity. October and later events are excluded from this widget.

28On board
16FDA / Reg
12Data / Filing
Aug 22Updated
FDA / PDUFA Clinical data Filing watch High risk Large cap
$NRXP KETAFREE Ongoing FDA review First-cycle review complete; manufacturer vial attestation submitted

NRx Pharmaceuticals. The July 29 GDUFA goal date has passed, but the ANDA remains active. On August 7, NRx reported that FDA completed its first-cycle review of the preservative-free intravenous ketamine ANDA with no major deficiencies related to the drug product, ingredients, proposed labeling, CMC or other drug-related review matters. The sole remaining major deficiency involved the container-closure system and a manufacturer attestation concerning the luer-lock vial. The same vial is used in three approved ANDA products that collectively shipped 11.9 million units in the United States over the prior 12 months, while the KETAFREE filing included testing of more than 3,500 vials from seven manufactured lots without observed luer-lock failures. On August 17, NRx confirmed that the requested manufacturer attestation had been submitted to FDA. No new exact action date has been disclosed.

$REGN Pasatru Aug 19 Approved Second FDA-approved treatment for FOP

Regeneron. On August 19, 2026 the FDA approved Pasatru (garetosmab-grts) to reduce the formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva, closing the August decision window the company had guided to without naming a day. Approval was based on the Phase 3 OPTIMA trial, which showed a 90 to 94 per cent reduction in new heterotopic ossification lesions and a decrease in flare-ups at 56 weeks. Pasatru is a fully human monoclonal antibody directed against activin A. The recommended starting dose is 10 mg/kg infused intravenously over 60 minutes once every four weeks, reducible to 3 mg/kg where the higher dose is not tolerated, and it can be administered across a range of care settings including home infusion. FDA describes it as the second approved treatment for FOP.

$CAPR deramiocel Aug 22* Extension expected BLA remains active; new 24-month data amendment planned

Capricor. The resubmitted deramiocel BLA remains under FDA review following the July 29 advisory committee vote of 9–3 against the sufficiency of the efficacy evidence for DMD-associated cardiomyopathy. Capricor subsequently said it plans to submit a BLA amendment incorporating 24-month HOPE-3 open-label-extension data and additional analyses focused on upper-limb function. The company has said FDA is willing to review the new information and that the August 22 deadline will be extended after the amendment is received. Until FDA or Capricor formally announces the revised action date, August 22 remains the last published PDUFA date but should no longer be treated as a fixed final-decision deadline.

$RARE GENGLYCOS Aug 19 Approved Accelerated approval four days ahead of the August 23 PDUFA

Ultragenyx. On August 19, 2026 the FDA granted accelerated approval to GENGLYCOS (pariglasgene brecaparvovec-opnr), previously known as DTX401, in adults and children aged eight years and older with glycogen storage disease type Ia. The decision landed four days before the August 23 PDUFA goal date the company had reaffirmed on August 4. The approved indication is narrower than the disease itself: the FDA label (STN 125858) covers the reduction of daily cornstarch intake as an adjunct to nutritional management, and continued approval may depend on verification of clinical benefit in confirmatory trials. The therapy can only be given to patients with no detectable anti-AAV8 antibodies, and the label carries warnings for hypersensitivity and infusion reactions, adrenal insufficiency and a theoretical risk of tumorigenicity from vector DNA integration. Approval rests on the 48-week randomised, double-blind, placebo-controlled Phase 3 GlucoGene study, which treated 46 participants and showed a statistically significant reduction in daily raw cornstarch requirements; the modified intention-to-treat population comprised 44 participants, 20 on DTX401 and 24 on placebo. It is the first gene therapy approval in the company history and its fifth FDA approval overall, and it carried a Priority Review Voucher.

$JAZZ Ziihera combo Aug 25 sBLA First-line HER2-positive GEA

Jazz Pharmaceuticals. Priority Review PDUFA for the Ziihera (zanidatamab-hrii) sBLA in combination with chemotherapy, with or without tislelizumab, for first-line locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma.

$GILD BIC/LEN Aug 27 NDA Once-daily oral HIV regimen

Gilead. Priority Review PDUFA for the bictegravir 75 mg/lenacapavir 50 mg NDA, a once-daily single-tablet regimen for virologically suppressed adults with HIV. This is a strategic lifecycle catalyst for the HIV franchise.

$PTGX rusfertide Q3 NDA Priority Review in polycythemia vera

Protagonist / Takeda. The rusfertide NDA in polycythemia vera is under Priority Review and no decision has been announced as of August 21. The joint Takeda and Protagonist announcement of the FDA filing acceptance, dated March 2, 2026, places the PDUFA goal date in the third quarter of 2026 without naming a month or a day, so the board shows the quarter rather than August. Rusfertide also holds Breakthrough Therapy, Orphan Drug and Fast Track designations. The submission rests on the Phase 3 VERIFY study together with the Phase 2 REVIEW study and the THRIVE long-term extension.

$TLX Pixclara Sep 11 PDUFA FDA decision on the resubmitted Pixclara NDA

Telix Pharmaceuticals. September 11, 2026 is the FDA PDUFA goal date for the resubmitted Pixclara (TLX101-Px) NDA. The application has already been submitted and accepted for review; the September catalyst is therefore the FDA decision on that NDA, not the NDA filing itself. Pixclara is a PET imaging agent intended to help characterize suspected recurrent or progressive glioma versus treatment-related changes.

$RARE UX111 Sep 19 BLA Gene therapy for Sanfilippo syndrome type A

Ultragenyx. PDUFA for the resubmitted UX111 (rebisufligene etisparvovec) BLA in Sanfilippo syndrome type A. The company reaffirmed September 19 in its August 4 update; the application seeks accelerated approval.

$MRK WINREVAIR Sep 21 sBLA PAH · HYPERION-based label update

Merck. PDUFA for an sBLA seeking a U.S. label update for WINREVAIR (sotatercept-csrk) based on the Phase 3 HYPERION study in pulmonary arterial hypertension. Merck reaffirmed the September 21 date with its second-quarter results.

$IONS zilganersen Sep 22 NDA Alexander disease

Ionis. Priority Review PDUFA for the zilganersen NDA in Alexander disease, a rare progressive neurological disorder. It remains one of September’s most closely watched rare-disease regulatory catalysts.

$GRAL Galleri Sep 23 FDA panel AdCom on the multi-cancer MCED test PMA

GRAIL. FDA’s Molecular and Clinical Genetics Panel will meet on September 23 to discuss and vote on the Galleri premarket approval application. Galleri is a blood-based multi-cancer early detection test proposed for screening adults aged 50 and older. This is not a drug PDUFA; it is a device and diagnostics regulatory catalyst that is nevertheless material to the stock.

$MIRM zilurgisertib Sep 26 NDA FOP · patients aged 12 and older

Mirum Pharmaceuticals / Incyte. Priority Review PDUFA for the zilurgisertib NDA in fibrodysplasia ossificans progressiva in patients aged 12 years and older. Mirum holds exclusive worldwide rights under license from Incyte.

$BFRI Ameluz PDT Sep 28 sNDA Expansion into superficial BCC

Biofrontera. PDUFA for the Ameluz photodynamic-therapy sNDA in superficial basal cell carcinoma. FDA completed its filing review without identifying filing deficiencies and assigned September 28 as the target action date.

$SRRK apitegromab Sep 30 BLA SMA · review continues with second fill-finish site

Scholar Rock. The apitegromab BLA in spinal muscular atrophy remains targeted to September 30. On August 7, the company said that, in coordination with FDA, Catalent Indiana is being removed from the BLA and review is continuing using the second fill-finish facility; the related data package is under review. CMC and manufacturing risk therefore remain central, while the company continues to state that the action date is unchanged.

$ROIV brepocitinib Q3 NDA Dermatomyositis · Priority Review

Priovant / Roivant. The brepocitinib NDA in dermatomyositis is under Priority Review. The company has disclosed a PDUFA target action date in the third quarter of 2026 and, if approved, has pointed to a possible U.S. launch around the end of September. No exact PDUFA day has been made public.

$QURE AMT-130 Q3 BLA Accelerated-approval BLA filing in Huntington’s disease

uniQure. The company is preparing an AMT-130 BLA in Huntington’s disease after alignment with FDA on a pathway that may use comparison with an external control as the primary basis of the application. The submission remains a Q3 2026 catalyst; it is not a PDUFA, and FDA filing acceptance would be the next formal step.

$IMMX NXC-201 Late Sep Data NEXICART-2 · AL amyloidosis

Immix Biopharma. The next NEXICART-2 update for NXC-201 in relapsed or refractory AL amyloidosis is expected in late September 2026. The program is designed as BLA-enabling/registrational, and subsequent follow-up is expected to contribute to the regulatory path.

$KPTI selinexor combo Aug sNDA Selinexor + ruxolitinib filing in myelofibrosis

Karyopharm. The former XPORT-EC-042 endometrial-cancer catalyst is resolved: on July 30, the study did not meet its primary progression-free-survival endpoint. The active event is now the sNDA the company plans to submit in August for selinexor combined with ruxolitinib in myelofibrosis, with a request for Priority Review.

$KOD DAYBREAK Sep Phase 3 Wet AMD · Zenkuda and KSI-501

Kodiak Sciences. One-year primary-endpoint topline results from the Phase 3 DAYBREAK study in wet age-related macular degeneration are expected in September 2026. The study evaluates Zenkuda (tarcocimab tedromer) and KSI-501 in parallel against aflibercept.

$ALMS envudeucitinib Q3 Data LUMUS Phase 2b in SLE

Alumis. Phase 2b LUMUS results for envudeucitinib in systemic lupus erythematosus are expected in the third quarter. For an autoimmune readout, the market will assess not only statistical significance but also dose consistency, clinical endpoints and the safety profile.

$IVVD VYD2311 Late Q3 Data DECLARATION pivotal study

Invivyd. Topline data from the pivotal DECLARATION study of VYD2311 are expected approximately toward the end of the third quarter of 2026. The timing remains company guidance rather than a calendar-specific date.

$PHVS deucrictibant XR Q3 Phase 3 CHAPTER-3 · HAE prophylaxis

Pharvaris. Phase 3 CHAPTER-3 topline data for extended-release deucrictibant in hereditary-angioedema prophylaxis remain expected in the third quarter of 2026. This is one of the quarter’s most important registrational HAE readouts.

$SYRE SPY003 Sep Data SKYLINE Phase 2 in ulcerative colitis

Spyre Therapeutics. SPY003 Part A topline data from the Phase 2 SKYLINE study are expected in September 2026. The company has now specified September rather than only the broader third-quarter window; no exact day has been disclosed.

$VERA TRUTAKNA / atacicept Q3 eGFR ORIGIN 3 confirmatory follow-up

Vera Therapeutics. The ORIGIN 3 eGFR analysis is expected in the third quarter following accelerated approval of atacicept. This is not another approval decision; its significance lies in the durability of the renal effect and the read-through for the confirmatory pathway.

$XENE azetukalner Q3 NDA Focal-onset seizure filing

Xenon. The azetukalner NDA submission in focal-onset seizures remains on track for the third quarter. Filing confirmation would begin FDA’s filing-review stage and set up a later PDUFA assignment.

$BBIO infigratinib Aug 10 NDA submitted Achondroplasia · FDA filing acceptance now becomes the next step

BridgeBio. BridgeBio confirmed on August 10, 2026 that it had submitted the NDA for oral infigratinib in achondroplasia to FDA. The former Q3 “submission” catalyst has therefore occurred. The program remains on the board because the regulatory process is materially open: FDA filing acceptance and any subsequent PDUFA assignment are now the next formal milestones. Infigratinib has Breakthrough Therapy, Fast Track and Rare Pediatric Disease designations in the United States.

$MLTX sonelokimab Late Sep BLA Hidradenitis suppurativa filing

MoonLake. The sonelokimab BLA submission in hidradenitis suppurativa is expected around the end of September 2026. FDA filing acceptance would create the next formal regulatory event.

Most attention-worthy watchlist

$NRXP $CAPR $RARE $PTGX $IONS $GRAL $MIRM $SRRK $PHVS $QURE $IMMX

Board rule

Only future or still materially unresolved catalysts through September are shown; catalysts resolved in the past few days are retained briefly for continuity. Two FDA approvals landed on August 19 and both stay on the board for now: $RARE/GENGLYCOS, cleared four days ahead of its August 23 PDUFA, and $REGN/Pasatru, which closed the August decision window Regeneron had guided to without naming a day. $AMLX/LUCIDITY has rolled off after one update; the August 18 Phase 3 readout was positive on the primary endpoint and on all secondary endpoints, and Amylyx still guides to an NDA by the end of 2026. $EYPT/LUGANO has been removed after EyePoint reported the readout on August 17; the full dataset did not meet the primary BCVA noninferiority endpoint, although an ad hoc analysis excluding nine patients supported noninferiority and several secondary measures were favorable. $TENX/LEVEL has been removed after the August 10 Phase 3 readout failed both the primary 6MWD endpoint and the key KCCQ-TSS secondary endpoint. $SLN/SANRECO has been removed after the August 10 positive Phase 2 results. $BMY/iberdomide has been removed after FDA granted accelerated approval to ZENBEXUS on August 13. $LNTH/TAUKLARIFY, approved on August 14, has also rolled off the board. $CLNN has been removed because Clene moved the planned CNM-Au8 ALS NDA submission to early Q4 2026, outside this widget. $NRXP remains because the requested manufacturer vial attestation has now been submitted to FDA but no new exact action date has been disclosed. $CAPR remains because the BLA review is still open. The August 22 date falls tomorrow and no revised action date has been announced as of August 21; the most recent company statement on the planned 24-month HOPE-3 amendment is the August 13 second-quarter update, in which Capricor said FDA had indicated it was willing to review the amendment and to extend the action date once it is received. $BBIO remains because the infigratinib NDA was submitted on August 10 and filing acceptance is now the next formal regulatory milestone. For $SYRE, company guidance now specifies September 2026 for SPY003. $PTGX moves from August to Q3 because the only primary-source statement on the rusfertide goal date, the March 2 filing-acceptance announcement, says third quarter of 2026 and names neither a month nor a day. $KPTI stays on an August window: as of its August 13 second-quarter update Karyopharm was on track to submit the selinexor plus ruxolitinib sNDA during August with a request for Priority Review, and no announcement confirming the submission has been found. Month-only and quarter-only windows reflect disclosed guidance and are not exact FDA dates.

Educational content only — not investment advice or a recommendation to buy or sell securities. Verify dates and primary filings before trading around binary events. Full catalyst calendar FDA SEC EDGAR

Biotech Catalyst Lookup

Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.

Disclaimer. This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security, in line with SEC (USA) guidance. Data is generated by AI from web sources and may contain errors or be out of date — always verify against the linked primary source. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.